These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26030078)

  • 21. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes to intellectual property policy in South Africa: putting a stop to evergreening?
    Hill JE
    Expert Opin Ther Pat; 2014 Aug; 24(8):839-43. PubMed ID: 24965317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is the pharmaceutical market in Bulgaria innovative?
    Stoimenova A; Stankova M; Samev K; Petrova G
    Boll Chim Farm; 2003 Sep; 142(7):260-3. PubMed ID: 14677267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Herbal drug patenting in India: IP potential.
    Sahoo N; Manchikanti P; Dey SH
    J Ethnopharmacol; 2011 Sep; 137(1):289-97. PubMed ID: 21640810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
    Matthews JH
    Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A trade agreement's impact on access to generic drugs.
    Shaffer ER; Brenner JE
    Health Aff (Millwood); 2009; 28(5):w957-68. PubMed ID: 19706626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential conflict between TRIPS and GATT concerning parallel importation of drugs and possible solution to prevent undesirable market segmentation.
    Lo CF
    Food Drug Law J; 2011; 66(1):73-83, ii. PubMed ID: 24505847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intellectual property rights, market competition and access to affordable antiretrovirals.
    Pascual F
    Antivir Ther; 2014; 19 Suppl 3():57-67. PubMed ID: 25309984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trials in India.
    Maiti R; M R
    Pharmacol Res; 2007 Jul; 56(1):1-10. PubMed ID: 17391981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):33-42. PubMed ID: 25138241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generic medicines: solutions for a sustainable drug market?
    Dylst P; Vulto A; Godman B; Simoens S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):437-43. PubMed ID: 23846572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generic medicines: issues and relevance for global health.
    Rana P; Roy V
    Fundam Clin Pharmacol; 2015 Dec; 29(6):529-42. PubMed ID: 26405851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interaction between intellectual property and drug regulatory systems: global perspectives.
    Madden EA
    IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
    Jain D; Darrow JJ
    Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Teva v. Eisai: what's the real "controversy"?
    Wang GL
    Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patent indicators: a window to pharmaceutical market success.
    Guo Y; Hu Y; Zheng M; Wang Y
    Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.